Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 287-291

  Lu Emerson, C ^a,b   Norden, A D ^a,b   Drappatz, J ^a,b   Quant, E C ^a,b   Beroukhim, R ^a   Ciampa, A S ^a   Doherty, L M ^a   Lafrankie, D C ^a   Ruland, S ^a   Wen, P Y ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bevacizumab failure; Dasatinib; Glioblastoma; High grade glioma; PDGFR beta inhibitor; SRC inhibitor

Indexed keywords

BEVACIZUMAB; DASATINIB;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER GROWTH; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; RIGOR; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES;

EID: 80052749324     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0489-x     Document Type: Article

References (47)

1. PY Wen S Kesari 2008 Malignant gliomas in adults N Engl J Med 359 492 507 18669428 10.1056/NEJMra0708126 1:CAS:528:DC%2BD1cXpt1Sgsrw%3D
2. MD Prados PH Gutin TL Phillips WM Wara DA Larson PK Sneed RL Davis DK Ahn K Lamborn CB Wilson 1992 Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989 Int J Radiat Oncol Biol Phys 23 3 8 1572829 10.1016/0360-3016(92)90537-R 1:STN:280:DyaK383kt1WksA%3D%3D
3. MD Prados W Seiferheld HM Sandler JC Buckner T Phillips C Schultz R Urtasun R Davis P Gutin TL Cascino HS Greenberg WJ Curran Jr 2004 Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404 Int J Radiat Oncol Biol Phys 58 1147 1152 15001257 10.1016/j.ijrobp.2003.08.024 1:CAS:528:DC%2BD2cXhslWmur4%3D (Pubitemid 38314798)
4. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
5. MJ van den Bent AF Carpentier AA Brandes M Sanson MJ Taphoorn HJ Bernsen M Frenay CC Tijssen W Grisold L Sipos H Haaxma-Reiche JM Kros MC van Kouwenhoven CJ Vecht A Allgeier D Lacombe T Gorlia 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2715 2722 16782911 10.1200/JCO.2005.04.6078 (Pubitemid 46630567)
6. KV Ballman JC Buckner PD Brown C Giannini PJ Flynn BR LaPlant KA Jaeckle 2007 The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro Oncol 9 29 38 17108063 10.1215/15228517-2006-025 1:CAS:528:DC%2BD2sXht1Ojs7w%3D (Pubitemid 46543486)
7. KR Lamborn WK Yung SM Chang PY Wen TF Cloughesy LM DeAngelis HI Robins FS Lieberman HA Fine KL Fink L Junck L Abrey MR Gilbert M Mehta JG Kuhn KD Aldape J Hibberts PM Peterson MD Prados 2008 Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro Oncol 10 162 170 18356283 10.1215/15228517-2007-062
8. ET Wong KR Hess MJ Gleason KA Jaeckle AP Kyritsis MD Prados VA Levin WK Yung 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572 2578 10561324 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D (Pubitemid 29368260)
9. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 967 974 16355214 10.1038/nature04483 1:CAS:528:DC%2BD2MXhtlSksrnI (Pubitemid 43093963)
10. G Gasparini R Longo M Toi N Ferrara 2005 Angiogenic inhibitors: a new therapeutic strategy in oncology Nat Clin Pract Oncol 2 562 577 16270097 10.1038/ncponc0342 1:CAS:528:DC%2BD2MXht1Ghu77F (Pubitemid 41721816)
11. JJ Vredenburgh A Desjardins JE Herndon II JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 17317837 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D (Pubitemid 46424067)
12. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592 603 18650835 10.1038/nrc2442 1:CAS:528:DC%2BD1cXovV2lsrk%3D
13. JM Ebos CR Lee RS Kerbel 2009 Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clin Cancer Res 15 5020 5025 19671869 10.1158/1078-0432.CCR-09-0095 1:CAS:528:DC%2BD1MXpvFeisrg%3D
14. G Bergers S Song N Meyer-Morse E Bergsland D Hanahan 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 1287 1295 12727920 1:CAS:528: DC%2BD3sXjsFCrsr4%3D (Pubitemid 36554699)
15. RK Jain MF Booth 2003 What brings pericytes to tumor vessels? J Clin Invest 112 1134 1136 14561696 1:CAS:528:DC%2BD3sXotlWisrc%3D (Pubitemid 38056288)
16. MR Mancuso R Davis SM Norberg S O'Brien B Sennino T Nakahara VJ Yao T Inai P Brooks B Freimark DR Shalinsky DD Hu-Lowe DM McDonald 2006 Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2610 2621 17016557 10.1172/JCI24612 1:CAS:528:DC%2BD28XhtVKgu7rO (Pubitemid 44511625)
17. P Baluk H Hashizume DM McDonald 2005 Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 102 111 15661540 10.1016/j.gde.2004.12.005 1:CAS:528:DC%2BD2MXmvFertQ%3D%3D (Pubitemid 40127638)
18. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 15637262 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar (Pubitemid 40093472)
19. M Hellstrom M Kalen P Lindahl A Abramsson C Betsholtz 1999 Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse Development 126 3047 3055 10375497 1:CAS:528:DyaK1MXlt1eqsrk%3D (Pubitemid 29378170)
20. P Lindahl BR Johansson P Leveen C Betsholtz 1997 Pericyte loss and microaneurysm formation in PDGF-B-deficient mice Science 277 242 245 9211853 10.1126/science.277.5323.242 1:CAS:528:DyaK2sXksFCksb0%3D (Pubitemid 27446080)
21. P Guo B Hu W Gu L Xu D Wang HJ Huang WK Cavenee SY Cheng 2003 Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment Am J Pathol 162 1083 1093 12651601 10.1016/S0002-9440(10)63905-3 1:CAS:528:DC%2BD3sXjtVemt7k%3D (Pubitemid 36350654)
22. A Abramsson P Lindblom C Betsholtz 2003 Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors J Clin Invest 112 1142 1151 14561699 1:CAS:528: DC%2BD3sXotlWis7w%3D (Pubitemid 38056291)
23. O Casanovas DJ Hicklin G Bergers D Hanahan 2005 Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 299 309 16226705 10.1016/j.ccr.2005.09.005 1:CAS:528:DC%2BD2MXhtFOrtLrF (Pubitemid 41443415)
24. R Du KV Lu C Petritsch P Liu R Ganss E Passegue H Song S Vandenberg RS Johnson Z Werb G Bergers 2008 HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion Cancer Cell 13 206 220 18328425 10.1016/j.ccr.2008.01.034 1:CAS:528:DC%2BD1cXjsVKgs74%3D (Pubitemid 351318372)
25. M Paez-Ribes E Allen J Hudock T Takeda H Okuyama F Vinals M Inoue G Bergers D Hanahan O Casanovas 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 220 231 19249680 10.1016/j.ccr.2009.01.027 1:CAS:528: DC%2BD1MXltFSmtbY%3D
26. A Angers-Loustau R Hering TE Werbowetski DR Kaplan RF Del Maestro 2004 SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions Mol Cancer Res 2 595 605 15561776 1:CAS:528:DC%2BD2cXhtVSqs73L (Pubitemid 39557663)
27. J de Groot V Milano 2009 Improving the prognosis for patients with glioblastoma: the rationale for targeting Src J Neurooncol 95 151 163 19436954 10.1007/s11060-009-9916-2
28. KV Lu S Zhu A Cvrljevic TT Huang S Sarkaria D Ahkavan J Dang EB Dinca SB Plaisier I Oderberg Y Lee Z Chen JS Caldwell Y Xie JA Loo D Seligson A Chakravari FY Lee R Weinmann TF Cloughesy SF Nelson G Bergers T Graeber FB Furnari CD James WK Cavenee TG Johns PS Mischel 2009 Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients Cancer Res 69 6889 6898 19690143 10.1158/0008-5472.CAN-09-0347 1:CAS:528:DC%2BD1MXhtVOmtL%2FL
29. LJ Lombardo FY Lee P Chen D Norris JC Barrish K Behnia S Castaneda LA Cornelius J Das AM Doweyko C Fairchild JT Hunt I Inigo K Johnston A Kamath D Kan H Klei P Marathe S Pang R Peterson S Pitt GL Schieven RJ Schmidt J Tokarski ML Wen J Wityak RM Borzilleri 2004 Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 6658 6661 15615512 10.1021/jm049486a 1:CAS:528:DC%2BD2cXhtVKrsrnI (Pubitemid 40053752)
30. TA Carter LM Wodicka NP Shah AM Velasco MA Fabian DK Treiber ZV Milanov CE Atteridge WH Biggs III PT Edeen M Floyd JM Ford RM Grotzfeld S Herrgard DE Insko SA Mehta HK Patel W Pao CL Sawyers H Varmus PP Zarrinkar DJ Lockhart 2005 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci USA 102 11011 11016 16046538 10.1073/pnas.0504952102 1:CAS:528:DC%2BD2MXnvVWjurg%3D (Pubitemid 41105984)
31. SA Doggrell 2005 BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia Expert Opin Investig Drugs 14 89 91 15709925 10.1517/13543784.14.1.89
32. GD Demetri P Lo Russo IR MacPherson D Wang JA Morgan VG Brunton P Paliwal S Agrawal M Voi TR Evans 2009 Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors Clin Cancer Res 15 6232 6240 19789325 10.1158/1078-0432.CCR-09-0224 1:CAS:528:DC%2BD1MXhtF2lurjM
33. EY Yu G Wilding E Posadas M Gross S Culine C Massard MJ Morris G Hudes F Calabro S Cheng GC Trudel P Paliwal CN Sternberg 2009 Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 7421 7428 19920114 10.1158/1078-0432.CCR-09-1691 1:CAS:528:DC%2BD1MXhsFSnu7vO
34. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
35. S Ananthnarayan J Bahng J Roring P Nghiemphu A Lai T Cloughesy WB Pope 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol 88 339 347 18389177 10.1007/s11060-008-9573-x
36. AD Norden GS Young K Setayesh A Muzikansky R Klufas GL Ross AS Ciampa LG Ebbeling B Levy J Drappatz S Kesari PY Wen 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 18316689 10.1212/01.wnl.0000304121.57857.38 1:CAS:528: DC%2BD1cXitlyqs7o%3D
37. EC Quant AD Norden J Drappatz A Muzikansky L Doherty D Lafrankie A Ciampa S Kesari PY Wen 2009 Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro Oncol 11 550 555 19332770 10.1215/15228517-2009-006 1:CAS:528:DC%2BD1MXhtlWht73P
38. FM Iwamoto LE Abrey K Beal PH Gutin MK Rosenblum VE Reuter LM DeAngelis AB Lassman 2009 Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73 1200 1206 19822869 10.1212/WNL. 0b013e3181bc0184 1:CAS:528:DC%2BD1MXht1antrfK
39. JF de Groot G Fuller AJ Kumar Y Piao K Eterovic Y Ji CA Conrad 2010 Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro Oncol 12 233 242 20167811
40. A Chi AD Norden PY Wen 2007 Inhibition of angiogenesis and invasion in malignant gliomas Expert Rev Anticancer Ther 7 1537 1560 18020923 10.1586/14737140.7.11.1537 1:CAS:528:DC%2BD1cXntlaqsA%3D%3D
41. J Drappatz AD Norden PY Wen 2009 Therapeutic strategies for inhibiting invasion in glioblastoma Expert Rev Neurother 9 519 534 19344303 10.1586/ern.09.10
42. K Porkka P Koskenvesa T Lundan J Rimpilainen S Mustjoki R Smykla R Wild R Luo M Arnan B Brethon L Eccersley H Hjorth-Hansen M Hoglund H Klamova H Knutsen S Parikh E Raffoux F Gruber F Brito-Babapulle H Dombret RF Duarte E Elonen R Paquette CM Zwaan FY Lee 2008 Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 112 1005 1012 18477770 10.1182/blood-2008-02-140665 1:CAS:528:DC%2BD1cXpvVOksL0%3D
43. P Borst RO Elferink 2002 Mammalian ABC transporters in health and disease Annu Rev Biochem 71 537 592 12045106 10.1146/annurev.biochem.71.102301.093055 1:CAS:528:DC%2BD38Xos1Clt74%3D (Pubitemid 34800230)
44. JS Lagas RA van Waterschoot VA van Tilburg MJ Hillebrand N Lankheet H Rosing JH Beijnen AH Schinkel 2009 Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment Clin Cancer Res 15 2344 2351 19276246 10.1158/1078-0432.CCR-08-2253 1:CAS:528:DC%2BD1MXjvVWlurg%3D
45. F Hyafil C Vergely P Du Vignaud T Grand-Perret 1993 In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res 53 4595 4602 8402633 1:CAS:528:DyaK2cXitlWnsA%3D%3D (Pubitemid 23304385)
46. SP Letrent GM Pollack KR Brouwer KLR Brouwer 1999 Effects of a potent and specific P-Glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat Drug Metab Dispos 27 827 834 10383928 1:CAS:528:DyaK1MXkt1CjsLc%3D (Pubitemid 29297782)
47. V Milano Y Piao T LaFortune J de Groot 2009 Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma Mol Cancer Ther 8 394 406 19190119 10.1158/1535-7163.MCT-08-0669 1:CAS:528:DC%2BD1MXhvFamsb8%3D